Inhibitory Effects of Zoledronic Acid-Loaded Bioresorbable Carrier on Osteosarcoma

Abstract:

Calcium phosphate cements have attracted much attention as a drug carrier for local administration of bisphosphonates which are widely used to treat bone diseases such as osteoporosis and bone tumors. In the present study, to design the novel drug delivery carrier for bone metastasis without undesirable side effects, zoledronic acid (ZOL) loaded-bioresorbable β-tricalcium phosphate (β-TCP) cement was fabricated on the basis of chelate-setting mechanism of inositol phosphate (IP6) using ZOL loaded-β-TCP powders. In order to examine the minimally effective concentration of ZOL on osteosarcoma with no effect on osteoblast viability, cells were treated with ZOL. At a concentration over 10 μM, ZOL significantly inhibited the proliferation of osteosarcoma, whereas osteoblasts proliferated normally. On the other hand, the ZOL showed concentration-dependent adsorption to IP6/β-TCP powders through chemisorption. Based on these results, we have fabricated ZOL loaded-IP6/β-TCP cements and evaluated the anti-tumor effect on osteosarcoma. We found that ZOL loaded-IP6/β-TCP cements have an inhibitory effect on osteosarcoma and induced apoptotic like-cell death. These results suggest that ZOL loaded-IP6/β-TCP cements are promising materials to develop the local treatment for bone metastasis.

• Periodical: Key Engineering Materials (Volume 782)
• Pages: 297-302
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.782.297
• Online since: October 2018
• Authors: Michiyo Honda*, Norihiro Suzuki, Kohei Nagata, Mamoru Aizawa
• Keywords: Anti-Tumor Effect, Bioresorbability, Calcium Phosphate Cement, Osteosarcoma, Zoledronic Acid

References

[1] S. Boissier, M. Ferreras, O. Peyruchaud, S. Magnetto, F.H. Ebetino, M. Colombel, P. Delmas, JM. Delaissé, P. Clézardin, Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases, Cancer Res., 60 (2000).

[2] G.R. Mundy, Metastasis to bone: causes, consequences and therapeutic opportunities, Nat. Rev. Cancer, 2 (2002) 584-593.

DOI: 10.1038/nrc867

[3] A.C. Hirbe, A.J. Rowlofs, D.H. Floyd, The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts, Bone, 44 (2009) 908-916.

DOI: 10.1016/j.bone.2009.01.010

[4] A. Bigi and E. Boanini, Calcium Phosphates as Delivery Systems for Bisphosphonates, J. Funct. Biomater., 9 (2018) 1-18.

[5] M.P. Ginebra, T. Traykova, J.A. Planell, Calcium phosphate cements as bone drug delivery systems: A review, J. Control. Release, 113 (2006) 102-110.

DOI: 10.1016/j.jconrel.2006.04.007

[6] T. Konishi, S. Takahashi, Z. Zhuang, K. Nagata, M. Mizumoto, M. Honda, Y.Takeuchi, H. Matsunari, H. Nagashima, M. Aizawa, Biodegradable b-tricalcium phosphate cement with anti-washout property based on chelate-setting mechanism of inositol phosphate, J. Mater. Sci.: Mater. Med., 24 (2013).

DOI: 10.1007/s10856-013-4903-8

[7] B. Ory, F. Blanchard, S. Battaglia, F. Gouin, F. Rédini and D. Heymann, Zoledronic Acid Activates the DNA S-Phase Checkpoint and Induces Osteosarcoma Cell Death Characterized by Apoptosis-Inducing Factor and Endonuclease-G Translocation Independently of p.53 and Retinoblastoma Status, Mol. Pharmacol., 71 (2007).

DOI: 10.1124/mol.106.028837

[8] R.G.G. Russell, N.B. Watts, F.H. Ebetino, M.J. Rogers, Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy, Osteoporos. Int., 19 (2008) 733-759.

DOI: 10.1007/s00198-007-0540-8

[9] H. Roussière, F. Fayon, B. Alonso, T. Rouillon, V. Schnitzler, E. Verron, J. Guicheux, M. Petit, D. Massiot, P. Janvier, J. Bouler, B. Bujoli, Reaction of Zoledronate with b-Tricalcium Phosphate for the Design of Potential Drug Device Combined Systems, Chem. Mater., 20 (2008).

DOI: 10.1021/cm702584d